Herb
    Moderate Evidence

    Pygeum

    Prunus africana

    TL;DR

    Pygeum africanum bark extract at 100-200 mg/day modestly improves urinary flow and nocturia in benign prostatic hyperplasia. A Cochrane review found roughly a 19% improvement in peak urine flow and two fewer night-time voids per week — real, but smaller than alpha-blockers and unlikely to change prostate volume.

    Ideal For

    • Men with mild to moderate BPH symptoms who have had a urological workup
    • Men whose main complaint is nocturia rather than obstructive symptoms
    • Those who did not tolerate alpha-blockers because of dizziness or ejaculatory effects
    • Men wanting an adjunct alongside standard therapy, with their clinician informed

    Avoid If

    • You have not had prostate cancer excluded by a clinician
    • You have acute urinary retention or blood in the urine — these need urgent assessment
    • You are relying on it instead of proven therapy for severe symptoms
    • You cannot verify sustainable, CITES-compliant sourcing

    Frequently Asked Questions

    How much improvement should I expect?
    The Cochrane pooled estimate is around a 19% increase in peak urinary flow and roughly two fewer nocturia episodes per week. Noticeable for mild symptoms, well short of what an alpha-blocker delivers for moderate to severe disease.
    Does pygeum lower PSA?
    No. Unlike finasteride, it does not measurably change PSA, so it will not distort prostate cancer screening. That is a genuine practical advantage.
    Pygeum or saw palmetto?
    Saw palmetto has larger, better-designed negative trials against it; pygeum has smaller, mostly positive but older ones. Neither is a substitute for medical therapy, and combining them makes it impossible to tell which is doing anything.
    Is the sourcing a problem?
    Yes. Prunus africana is CITES Appendix II listed after decades of destructive wild bark harvesting. Buy only from suppliers documenting sustainable or cultivated sourcing.

    Overview

    Prunus africana bark has been used in African traditional medicine for urinary complaints and has been a registered BPH treatment in France and Italy for decades. The Cochrane review pooling 18 randomised trials in over 1,500 men found consistent, modest symptomatic benefit: improved peak and mean urinary flow, reduced residual volume and fewer nocturia episodes, with adverse-event rates similar to placebo. What it does not do is shrink the prostate or alter PSA, which distinguishes it mechanistically from 5-alpha-reductase inhibitors and means it cannot mask a rising PSA on screening. Most trials are short, run before modern symptom-score standardisation, and used a lipophilic bark extract that is not consistently replicated across retail products. The other complication is ecological: wild harvesting drove Prunus africana onto CITES Appendix II, so sourcing matters. Treat pygeum as a reasonable adjunct for mild to moderate lower urinary tract symptoms after a urological assessment, not as a substitute for one.

    How It Works

    • Phytosterols including beta-sitosterol inhibit prostaglandin synthesis in prostatic tissue
    • Pentacyclic triterpenes reduce oedema and inflammation at the bladder neck
    • Ferulic acid esters reduce cholesterol availability for local androgen synthesis
    • Inhibits fibroblast growth factor activity implicated in stromal proliferation
    • Restores bladder contractility in models of outlet obstruction
    • No measurable effect on serum testosterone, DHT or PSA

    Quick Facts

    • Traditional prostate remedy
    • Improves urinary symptoms
    • Reduces prostate inflammation
    • Supports urinary flow
    • Anti-inflammatory effects

    Supporting Research
    4 studies

    Pygeum africanum for benign prostatic hyperplasia

    Score: 8/10
    2002
    systematic_review
    n=1562

    Wilt T, Ishani A, Mac Donald R +2 more

    Across 18 randomised trials Pygeum africanum improved urologic symptoms and peak urine flow versus placebo, with adverse events comparable to placebo.

    View source

    Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis

    Score: 7/10
    2000
    meta_analysis
    n=1562

    Ishani A, MacDonald R, Nelson D +2 more

    Men taking Pygeum africanum were more than twice as likely to report improved overall symptoms, with reduced nocturia and residual urine volume.

    View source

    Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study

    Score: 5/10
    1999
    rct
    n=209

    Chatelain C, Autet W, Brackman F

    Both 100 mg once daily and 50 mg twice daily reduced IPSS by about 38 percent with benefit maintained one month after withdrawal.

    View source

    Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia: a multicentre trial in central Europe

    Score: 4/10
    1998
    observational
    n=85

    Breza J, Dzurny O, Borowka A +4 more

    Two months of Tadenan 50 mg twice daily reduced IPSS by 40 percent with benefit largely sustained after a one month washout.

    View source

    Safety Information

    Potential Side Effects

    Generally well tolerated. Mild gastrointestinal upset, nausea and abdominal pain are the most reported effects and occur at rates close to placebo in pooled trials.

    Contraindications

    Undiagnosed lower urinary tract symptoms, suspected prostate malignancy, acute urinary retention.

    Drug Interactions

    • No established pharmacokinetic interactions
    • Additive symptomatic effect with alpha-blockers such as tamsulosin — not a safety issue but confounds assessment
    • Theoretical additive effect with 5-alpha-reductase inhibitors, though mechanisms differ

    Pregnancy & Breastfeeding

    Pregnancy: Not enough evidence to judge

    Breastfeeding: Not enough evidence to judge

    Dosage Guidelines

    Dosage Used in Studies

    50-200 mg

    Best Time to Take

    With meals, split morning and evening

    Best Form

    Standardised lipophilic bark extract at 13% sterols, 100 mg/day

    Bioavailability

    The active fraction is lipophilic and absorption improves with dietary fat. Human pharmacokinetics are poorly characterised, and standardisation to sterol content is the only practical quality marker.

    Dosing by Goal

    GoalDoseNotes
    Standard100 mg/day, either as one dose or 50 mg twice daily
    TimingWith food to reduce gastrointestinal upset
    Trial durationMost positive trials ran 30-90 days
    AssessmentRe-score IPSS at 8 weeks and discontinue if unchanged
    Upper range200 mg/day used in some trials with no added toxicity

    Forms Compared

    Standardised lipophilic bark extract

    13% total sterols, 0.5% n-docosanol — the specification used in trials

    50 mg twice-daily capsules

    The most common trial regimen

    100 mg once-daily capsules

    Equivalent daily exposure with better adherence

    Pygeum plus saw palmetto combinations

    Popular, but effect attribution between the two becomes impossible

    Raw bark powder

    Unstandardised sterol content; not a therapeutic form

    Food & Timing

    With meals; taking the evening dose after dinner suits nocturia-dominant symptoms

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.